Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma
Source: Oncology Nurse Advisor, February2016
Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with BRAF V600 mutation-positive metastatic melanoma, a study published online ahead of print in the Journal of Clinical Oncology has shown.1
This analysis reports on the overall survival (OS) and clinical characteristics of BRAF inhibitor–naive long-term responders and survivors treated with dabrafenib plus trametinib from a phase I and II study of patients with BRAF V600 mutation-positive metastatic melanoma.
This analysis included 78 BRAF inhibitor–naive patients treated with dabrafenib 150 mg twice daily plus trametinib 2 mg daily (the 150/2 group): 24 patients were from the nonrandomly assigned (part B) cohort and 54 patients were from the randomly assigned (part C) cohort of the trial.